WNT1 and prostate carcinoma: To further elucidate how the active ingredients in XHP regulate the Wnt pathway and influence prostate cancer proliferation, we conducted molecular docking using LC-MS/MS-identified active compounds as ligands and the key target protein, Wnt1, as the receptor.